|
|
 |
|
Viewing report
|
|
|
|
MDxHealth SA (ONCOB) - Product Pipeline Analysis
GlobalData, Nov 2011, Pages: 40
MDxHealth SA (ONCOB) - Product Pipeline Analysis
Summary
MDxHealth SA (MDxHealth) is a publicly held molecular diagnostics company that is engaged in developing gene methylation tests for early cancer detection and treatment. The company serves physicians by developing novel molecular tests for detecting cancer. MDxHealth products include treatment products, molecular cancer diagnostics, personalized treatment solutions which are used in the diagnosis of various cancers including prostate cancer, colorectal cancer, bladder cancer, breast cancer, lung cancer, cervical cancer. It also offers MGMT testing services including clinical trial testing, patient testing. In addition, the company focuses on clinical development by collaborating with cancer research institutions. MDxHealth has entered in to agreement with F. Hoffmann-La Roche Ltd., of Basel Switzerland, for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed (glioblastoma [GBM]) brain tumors. It was formerly known as OncoMethylome Sciences SA. MDxHealth is headquartered in Liege, Belgium.
This report is a source for data, analysis and actionable intelligence on the MDxHealth SA portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.
Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.
Reasons to Buy
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.
|
|
|
|
